...soon follow, as both the Phase III ARCHES trial of Xtandi and the Phase III TITAN... ...Placebo + prednisone (n=602) NA 14.8 36.5 Johnson & Johnson (NYSE:JNJ) Erleada apalutamide Ph III TITAN... ...co-primary endpoints of overall survival (OS) and radiographic progression-free survival (rPFS) in the Phase III TITAN...
...an IDMC showed that Erleada apalutamide met the dual primary endpoints in the Phase III TITAN... ...approval of the second-generation androgen receptor antagonist in the indication are expected this year. On TITAN's...
...an IDMC showed that Erleada apalutamide met the dual primary endpoints in the Phase III TITAN... ...approval of the second-generation androgen receptor antagonist in the indication are expected this year. On TITAN's...
...marketed buprenorphine products -- once-monthly injectable Sublocade from Indivior plc (LSE:INDV) and implant Probuphine from Titan Pharmaceuticals Inc.... ...Alkermes lost $0.60 to $40.09 on Monday, while Indivior was up 8.60p to 268.30p and Titan... ...buprenorphine
Sublocade (Brand), RBP-6000 (Compound #), buprenorphine (Generic)
Vivitrol, naltrexone (Medisorb naltrexone, Vivitrex, XR-NTX)
Alkermes plc
Braeburn Pharmaceuticals Inc.
Indivior plc
Titan Pharmaceuticals Inc.
ICER
MATs
medication-assisted...
...products -- the once-monthly injectable Sublocade from Indivior plc (LSE:INDV) and the implant Probuphine from Titan Pharmaceuticals Inc.... ...England Comparative Effectiveness Public Advisory Council (CEPAC) on November 8.
Mary Romeo
CAM2038
Methadone
Probuphine
Sublocade
Suboxone sublingual film
Vivitrol
Braeburn Pharmaceuticals Inc.
Indivior plc
Titan Pharmaceuticals Inc....
...soon follow, as both the Phase III ARCHES trial of Xtandi and the Phase III TITAN... ...Placebo + prednisone (n=602) NA 14.8 36.5 Johnson & Johnson (NYSE:JNJ) Erleada apalutamide Ph III TITAN... ...co-primary endpoints of overall survival (OS) and radiographic progression-free survival (rPFS) in the Phase III TITAN...
...an IDMC showed that Erleada apalutamide met the dual primary endpoints in the Phase III TITAN... ...approval of the second-generation androgen receptor antagonist in the indication are expected this year. On TITAN's...
...an IDMC showed that Erleada apalutamide met the dual primary endpoints in the Phase III TITAN... ...approval of the second-generation androgen receptor antagonist in the indication are expected this year. On TITAN's...
...marketed buprenorphine products -- once-monthly injectable Sublocade from Indivior plc (LSE:INDV) and implant Probuphine from Titan Pharmaceuticals Inc.... ...Alkermes lost $0.60 to $40.09 on Monday, while Indivior was up 8.60p to 268.30p and Titan... ...buprenorphine
Sublocade (Brand), RBP-6000 (Compound #), buprenorphine (Generic)
Vivitrol, naltrexone (Medisorb naltrexone, Vivitrex, XR-NTX)
Alkermes plc
Braeburn Pharmaceuticals Inc.
Indivior plc
Titan Pharmaceuticals Inc.
ICER
MATs
medication-assisted...
...products -- the once-monthly injectable Sublocade from Indivior plc (LSE:INDV) and the implant Probuphine from Titan Pharmaceuticals Inc.... ...England Comparative Effectiveness Public Advisory Council (CEPAC) on November 8.
Mary Romeo
CAM2038
Methadone
Probuphine
Sublocade
Suboxone sublingual film
Vivitrol
Braeburn Pharmaceuticals Inc.
Indivior plc
Titan Pharmaceuticals Inc....